| Global Pharma Sales Steadily Growing Despite Rise of Generics The Burrill Report submits: The size of the global market for pharmaceuticals is expected to grow nearly $300 billion over the next five years, reaching $1.1 trillion in 2014, according to the pharmaceutical market research firm IMS Health. Overall, IMS says the drug sales will grow at a compounded annual rate of 5 to 8 percent. Growth in emerging countries will help offset the large number of leading products losing patent protection during this period. Over the next five years, products with sales of more than $142 billion are expected to face generic competition in major developed markets. Collectively, the impact of patients shifting to lower-cost generics in major therapy areas such as cholesterol regulators, antipsychotics, and anti-ulcerants will reduce total drug spending by about $80 to $100 billion worldwide through 2014. This impact particularly will be felt in the United States, where nearly two-thirds of the total value of patent expiries will occur. Patent expiries in the United States will peak in 2011 and 2012 when six of today’s ten largest products are expected to face generic competition. Complete Story » seekingalpha.com |
Hospitals' Woes Grow With State Cuts Chiefs at some of New York City's largest hospitals say that state cuts in Medicaid and other health-care spending passed by the legislature would harm financially weak health centers and could force even stronger ones to cut workers or care. online.wsj.com |
Kensey Nash, Because Biomaterials Is a Growth Industry Jim Van Meerten submits: Kensey Nash Corporation (KNSY) designs, develops, manufactures, and processes proprietary biomaterials products for the orthopedics, cardiology,drug/biologics delivery and wound care markets. The company also is involved with cardiovascular medical technology, specifically, arterial revascularization and puncture closure devices. The company intends to leverage its proprietary knowledge and expertise to develop new products and technologies and to explore additional applications for its products. In the last 30 days this stock has appreciated 14.71% with 15 new highs in the last 20 trading sessions. On Barchart 12 of the 13 technical indicators have buys for a 96% technical buy signal. The stocks trades at 24.10 with a 50 day moving average of 22.87.Complete Story » seekingalpha.com |
Salmonella Is No Danger to Vaccines This year's flu vaccine has some consumers worried. While it might protect them against a potentially deadly virus, could they end up infected with salmonella instead? online.wsj.com |
Crest Video with Dr. Travis Stork - Video Crest® and Oral-B® Partner with Tiffani Thiessen to Declare September National Gingivitis Awareness Month feedproxy.google.com |